Study Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Want to learn more about this trial?
Request More InfoInterventions
Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basisDRUG
A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 1.0-5.0 x10\^5 CART cells/kg）.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital of University of Science and Technology of China | Hefei | China |